Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -120K | -127K | -122K | -121K | 0 |
| Operating Income | -2M | -3M | -3M | -2M | -2M |
| EBITDA | -2M | -4M | -6M | -3M | -2M |
| Net Income | -3M | -4M | -7M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.56
-2.50% today
1Y Change
-82.44%
Window
Jun 26, 2025 → Jun 17, 2026
Coverage: 245 bars · Jun 26, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jyong Biotech Ltd. Ordinary Shares (MENS) is a Healthcare stock with a market cap of $170.00M and listed on NASDAQ. The stock last traded around $1.56 and down 82.4% across the available one-year price window (Jun 26, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.4%, free cash flow -39.3% with operating margin 0.0% and ROIC -2.5%. Stock Foundry combines MENS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MENS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MENS Max Drawdown
-97.78%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MENS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.9M
+54.4% YoY
Free Cash Flow
-$1.2M
+44.6% YoY
Revenue Growth
+0.0%
EPS Growth
+31.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -120K | -127K | -122K | -121K | 0 |
| Operating Income | -2M | -3M | -3M | -2M | -2M |
| EBITDA | -2M | -4M | -6M | -3M | -2M |
| Net Income | -3M | -4M | -7M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 98K | 177K | 718K | 551K | 4M |
| Total Assets | 6M | 8M | 9M | 9M | 13M |
| Total Liabilities | 43M | 42M | 38M | 33M | 32M |
| Shareholder Equity | -37M | -34M | -30M | -23M | -19M |
| Total Debt | 18M | 17M | 14M | 12M | 14M |
| Net Debt | 18M | 17M | 14M | 11M | 10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+45.2% YoY
Capital Expenditures
88K
+35.8% YoY
Free Cash Flow
1M
+44.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
4.2%
Debt / Equity
-1.57x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.